Growth hormone is not released in a steady drip. It is released in roughly six to ten pulses across 24 hours, and one pulse dominates: the nocturnal burst, which begins within 30–60 minutes of sleep onset and coincides almost exactly with the first episode of slow-wave sleep (SWS, also called N3 or delta sleep). Eve Van Cauter and colleagues mapped this relationship across decades of polysomnography studies and showed that more than 70% of the daily GH output in young adults occurs during this single nocturnal window.
The driver is hypothalamic GHRH. As the cortex slows into delta-dominant SWS, GHRH neurons in the arcuate nucleus fire, somatostatin tone falls, and the pituitary releases its largest GH bolus of the day. Crucially, GHRH itself is somnogenic — Obal and Krueger demonstrated that GHRH administration directly increases SWS duration, while GHRH antagonism reduces it. The relationship is bidirectional: sleep drives GH, and GHRH drives sleep.
This is the entire reason tesamorelin — a GHRH(1–44) analog stabilized against dipeptidyl peptidase-IV cleavage — works best as an evening injection. Buy tesamorelin UAE 24h delivery if you want to align research dosing with this physiology.
Tesamorelin (trade name Egrifta) is a 44-amino-acid synthetic analog of human GHRH with a single trans-3-hexenoyl modification at the N-terminus. This modification protects against DPP-IV cleavage, extending plasma half-life from minutes (native GHRH) to roughly 26–38 minutes for tesamorelin. It is FDA-approved for HIV-associated lipodystrophy (visceral fat reduction) on the back of Falutz 2007 and Stanley 2014.
It is not GH. It does not bypass the pituitary. It signals upstream — to the somatotrophs — and asks the pituitary to release its own GH in its own pulsatile pattern. Three implications follow:
Slow-wave sleep is N3 in modern AASM scoring — the stage characterized by EEG delta activity (0.5–4 Hz) at greater than 20% of an epoch. It is concentrated in the first third of the night and declines with age: a healthy 25-year-old spends roughly 90–110 minutes per night in SWS; a 60-year-old typically logs 30–50 minutes; a 75-year-old may record under 20 minutes. This SWS decline parallels the age-related decline in GH secretion almost perfectly — Van Cauter's 2000 JAMA paper made this link directly.
Steiger and colleagues (Munich Max Planck Institute) ran the foundational studies on GHRH and sleep. A 4 x 50 µg pulsatile GHRH infusion during the first half of the night increased SWS by ~25% and increased GH AUC, with the largest effects in older subjects who had the most SWS deficit at baseline. The mechanism is dual: GHRH binds GHRH receptors in the preoptic area (sleep-promoting), and the resulting GH pulse feeds back via IGF-1 to support consolidation.
REM sleep is governed by a different circuit — cholinergic REM-on neurons in the laterodorsal and pedunculopontine tegmental nuclei, gated by aminergic REM-off neurons in the locus coeruleus and dorsal raphe. GHRH does not directly drive REM. However, three observed effects on REM are worth flagging:
For research applications targeting cognitive consolidation or recovery from shift-work disruption, the REM-stabilizing effect is often as valuable as the SWS amplification.
Tesamorelin reaches plasma T-max approximately 15 minutes after subcutaneous injection, with a t½ of ~26 minutes in healthy subjects (longer in HIV-lipodystrophy populations). The GH pulse it triggers peaks 30–60 minutes post-injection and lasts 60–90 minutes. Therefore:
| Injection time (relative to sleep onset) | Effect on nocturnal pulse |
|---|---|
| 3+ hours before bed | Pulse occurs during wakefulness — wasted physiology, may blunt natural SWS-locked pulse |
| 60–90 min before bed | OPTIMAL — tesamorelin pulse stacks with endogenous SWS-locked pulse |
| 0–30 min before bed | Acceptable; pulse arrives during early N2/N3 transition |
| Morning | Triggers daytime pulse against high somatostatin tone — reduced amplitude, no sleep benefit |
The 60–90 minute window is the consensus among researchers working with GHRH-class peptides. It avoids two failure modes: injecting too late (pulse arrives during deep SWS and may briefly fragment it) and injecting too early (pulse fires during evening alertness when somatostatin is high and the response is blunted).
Falutz 2007 and Stanley 2014 used 2 mg subcutaneous daily for visceral fat endpoints. Sleep-architecture research with GHRH-class peptides has tested both lower (1 mg) and standard (2 mg) evening doses. Higher doses do not appear to deepen SWS proportionally — the SWS effect saturates while IGF-1 continues to rise, suggesting the sleep benefit is dose-independent above ~1 mg in non-deficient subjects.
| Dose | Typical use | IGF-1 response (4 wk) | SWS effect |
|---|---|---|---|
| 1 mg SC evening | Sleep architecture, gentle GH support | +30–50% | Measurable SWS lift |
| 2 mg SC evening | Standard Falutz/Stanley protocol | +60–100% | SWS lift plateaus |
| 2 mg SC morning | Not recommended for sleep endpoints | +60–100% | No sleep benefit |
REVIVE LAB holds tesamorelin in temperature-controlled Dubai stock. The supply chain is built specifically for the UAE research market — no international waiting times, no customs holds, no broken cold chain in summer heat.
| Emirate | Order cutoff | Delivery window |
|---|---|---|
| Dubai | 3 PM | Same-day, 6–10 PM |
| Abu Dhabi | 3 PM | Next-day, by noon |
| Sharjah | 3 PM | Same-day, 6–10 PM |
| Ajman | 3 PM | Next-day, morning |
| Ras Al Khaimah | 3 PM | Next-day, by 2 PM |
| Fujairah | 3 PM | Next-day, afternoon |
| Umm Al Quwain | 3 PM | Next-day, morning |
Tesamorelin is shipped lyophilized — it tolerates 2–8 °C in transit and accepts brief room-temperature excursions, but UAE summer dispatch still uses gel packs and insulated mailers. Once reconstituted with bacteriostatic water, tesamorelin must be refrigerated continuously and used within 7–14 days for sleep-research applications where pulse amplitude is the endpoint.
The GH-secretagogue landscape includes GHRH analogs (tesamorelin, sermorelin, CJC-1295), ghrelin mimetics (ipamorelin, GHRP-6, MK-677), and direct GH (somatropin). Only GHRH analogs preserve the natural SWS-locked pulse architecture. Ghrelin mimetics drive GH via a parallel pathway and can disturb sleep in some subjects (MK-677 in particular has reported daytime fatigue and morning grogginess). Direct GH bypasses the entire pulse system and flattens the diurnal curve.
For sleep-architecture endpoints specifically, tesamorelin is the cleanest tool because it amplifies the existing SWS pulse without introducing competing kinetics. See our tesamorelin vs sermorelin comparison for the head-to-head detail.
Dubai's summer ambient temperatures regularly exceed 45 °C, and a car interior can exceed 70 °C within 20 minutes. Tesamorelin tolerates room temperature briefly but lyophilized stability data is built around 2–8 °C continuous storage. Practical points:
See the UAE peptide storage guide for full thermal protocols.
REVIVE LAB stocks tesamorelin 5 mg and 10 mg vials in Dubai with same-day dispatch and 24h delivery to all seven emirates. Order before 3 PM Dubai time for same-day cold-chain handoff. Buy tesamorelin UAE 24h delivery here.
Because the GH pulse that tesamorelin amplifies is sleep-locked. Morning dosing fires the pulse against high somatostatin tone and wastes the SWS-amplification effect.
Indirectly, yes. SWS consolidation in the early night leaves more time for uninterrupted REM cycles later, and many users report longer, more vivid dreams within 2–3 weeks.
In published GHRH-class sleep studies, no — it generally improves both SWS duration and sleep continuity. Subjective reports of "too-vivid" early dreams usually settle by week 3.
MK-677 is a ghrelin mimetic with a long half-life that flattens the daily GH curve and is associated with morning grogginess in some users. Tesamorelin preserves pulsatility and is the cleaner tool for sleep-architecture endpoints.